Ocata Therapeutics Inc fka OCAT

[rumper]

OCAT Makes Lucentis and Eylea OBSOLETE

And these 2 Drugs have combined sales of $6 Billion
And REGN has a $40 Billion Market Cap that OCAT
can now destroy with their technology.

This is not going to be pretty. But it's going to be fun.

Speaking about wet AMD.
PW: But what we're actually going to be able
to do is to catch these patients, before they
have to need to be treated with Lucentis or
Eylea.

PW: Our RPE Transplant Therapy takes care
of all three of these disorders.

Speaking about SMD, AMD, and MMD.
And since it is 'curative' it makes obsolete
all palliative treatment.

PW: For those of you who are familiar with
breakthrough stories in biotech or anywhere
else...the cells are actually going to be
given by retinal injection. Which is a technique
that's already used by physicians today. So
we're not asking them to do something they
don't know how to do.


Ted: This is a small company, but it controls its
destiny. We've got the manufacturing piece down.
We feel that we've got a lot of the foundation of
the fundamentals of the technology very well
mastered.

This is saying, 'we can go it alone' from the
technical side, the IP side

Roadshow 1.0